Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome

Lorenzo Cavagna(Società Italiana di Reumatologia), Laura Nuño(Hospital Universitario La Paz), Carlo Alberto Scirè(Società Italiana di Reumatologia), Marcello Govoni(University of Ferrara), Francisco Longo(Hospital General Universitario Gregorio Marañón), Franco Franceschini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), R Neri(University of Pisa), Santos Castañeda(Hospital Universitario de La Princesa), Walter Alberto Sifuentes Giraldo(Hospital Universitario Ramón y Cajal), Roberto Caporali(University of Bari Aldo Moro), Florenzo Iannone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Enrico Fusaro(Ospedale Santa Chiara), Giuseppe Paolazzi(A. O. Ordine Mauriziano di Torino), Raffaele Pellerito(Johannes Gutenberg University Mainz), Andreas Schwarting(Tulane University), Lesley Ann Saketkoo(Instituto de Investigación Biosanitaria de Granada), Norberto Ortego‐Centeno(Ospedale Santa Maria della Misericordia di Udine), Luca Quartuccio(University of Perugia), Elena Bartoloni(St. Josef Krankenhaus), Christof Specker(Universidad de Cantabria), Trinitario Pina Murcia(Acura Kliniken), Renato La Corte(University of Ferrara), Federica Furini(Guglielmo da Saliceto Hospital), Valentina Foschi(University of Ferrara), Javier Bachiller‐Corral(Hospital Universitario Ramón y Cajal), Paolo Airó(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Ilaria Cavazzana(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Julia Martínez‐Barrio(Universidad Complutense de Madrid), Michelle Hinojosa(Universidad Complutense de Madrid), Margherita Giannini(University of Bari Aldo Moro), Simone Barsotti(University of Pisa), Julia Menke(Johannes Gutenberg University Mainz), Kostantinos Triantafyllias, Rosetta Vitetta(Ospedali Riuniti Umberto I), Alessandra Russo(Ospedali Riuniti Umberto I), Gianluigi Bajocchi(Santa Maria Nuova Hospital), Elena Bravi(Guglielmo da Saliceto Hospital), Giovanni Barausse, Roberto Bortolotti, Carlo Selmi(Fondazione Humanitas per la Ricerca), Simone Parisi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Carlomaurizio Montecucco(Policlinico San Matteo Fondazione), Miguel Á. González‐Gay(Marqués de Valdecilla University Hospital)
Medicine
August 1, 2015
Cited by 180Open Access
Full Text

Abstract

Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). These manifestations usually co-occur (for practical purpose complete forms) in the same patient, but cases with only 1 or 2 of these findings (for practical purpose incomplete forms) have been described. In incomplete forms, the ex novo occurrence of further manifestations is possible, although with frequencies and timing not still defined. The aim of this international, multicenter, retrospective study was to characterize the clinical time course of anti Jo-1 positive ASSD in a large cohort of patients. Included patients should be anti Jo-1 positive and with at least 1 feature between arthritis, myositis, and ILD. We evaluated the differences between complete and incomplete forms, timing of clinical picture appearance and analyzed factors predicting the appearance of further manifestations in incomplete ASSD. Finally, we collected 225 patients (58 males and 167 females) with a median follow-up of 80 months. At the onset, complete ASSD were 44 and incomplete 181. Patients with incomplete ASSD had frequently only 1 of the classic triad findings (110 cases), in particular, isolated arthritis in 54 cases, isolated myositis in 28 cases, and isolated ILD in 28 cases. At the end of follow-up, complete ASSD were 113, incomplete 112. Only 5 patients had an isolated arthritis, only 5 an isolated myositis, and 15 an isolated ILD. During the follow-up, 108 patients with incomplete forms developed further manifestations. Single main feature onset was the main risk factor for the ex novo appearance of further manifestation. ILD was the prevalent ex novo manifestation (74 cases). In conclusion, ASSD is a condition that should be carefully considered in all patients presenting with arthritis, myositis, and ILD, even when isolated. The ex novo appearance of further manifestations in patients with incomplete forms is common, thus indicating the need for an adequate clinical and instrumental follow-up. Furthermore, the study clearly suggested that in ASSD multidisciplinary approach involving Rheumatology, Neurology, Pneumology, and Internal Medicine specialists is mandatory.


Related Papers

No related papers found

Powered by citation graph analysis